ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,447.90
0.14%
S&P ASX All Technology
3,966.40
0.06%
Brent Oil
72.055
-0.03%
US Dollar vs AUD
1.55111
0.84%
Bitcoin
97,399.14
0.14%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Zymeworks Inc (ZYME)

  7. Zymeworks Inc (ZYME) News

ZYME

Zymeworks (ZYME)

Zymeworks Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:ZYME
DateTimeSourceHeadlineSymbolCompany
30/06/202306:12Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
22/06/202306:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ZYMEZymeworks Inc
13/06/202306:26Edgar (US Regulatory)Amended Securities Registration (section 12(b)) (8-a12b/a)NYSE:ZYMEZymeworks Inc
13/06/202306:07Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
05/06/202320:03Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
03/06/202309:23PR Newswire (US)Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract CancersNYSE:ZYMEZymeworks Inc
18/05/202322:41Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
16/05/202322:31Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
09/05/202307:20Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NYSE:ZYMEZymeworks Inc
09/05/202306:14Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
29/04/202306:18Edgar (US Regulatory)Amended Annual Report (10-k/a)NYSE:ZYMEZymeworks Inc
26/04/202322:31Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
11/04/202306:46Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
16/03/202307:17Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
15/03/202308:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ZYMEZymeworks Inc
08/03/202309:25Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NYSE:ZYMEZymeworks Inc
08/03/202308:09Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
15/02/202308:47Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:ZYMEZymeworks Inc
15/02/202308:02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:ZYMEZymeworks Inc
15/02/202306:38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:ZYMEZymeworks Inc
11/02/202309:29Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:ZYMEZymeworks Inc
26/01/202300:30Business WireZymeworks Announces Participation in Upcoming Investor ConferencesNYSE:ZYMEZymeworks Inc
24/01/202310:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ZYMEZymeworks Inc
20/01/202300:11Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
19/01/202323:45PR Newswire (US)Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal AdenocarcinomaNYSE:ZYMEZymeworks Inc
19/01/202323:45PR Newswire (US)Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal AdenocarcinomaNYSE:ZYMEZymeworks Inc
13/01/202308:48Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ZYMEZymeworks Inc
05/01/202308:22Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
05/01/202308:15Business WireZymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023NYSE:ZYMEZymeworks Inc
04/01/202309:02Edgar (US Regulatory)Statement of Ownership (sc 13g)NYSE:ZYMEZymeworks Inc
 Showing the most relevant articles for your search:NYSE:ZYME

Your Recent History

BIT
FLEQ
Franklin Temp ICAV - Fra...
BIT
P1QA51
BNP Paribas Issuance
TG
V720
Betsson AB
BIT
P1L7J4
BNP Paribas Issuance
BIT
P1TRD9
BNP Paribas Issuance
UNSW3
HYPEETH
HypeToken.vip
CSE
TAUR
Taurus Gold
AQSE
2VIS.GB
Leverage Shares 2x Visa ...
USOTC
CMPCY
Compal Electronics (PK)
FX
GBPMAD
Sterling vs MAD
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for ASX Level 1 & 2

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1958.40 only $783.36